본문 바로가기
KERD
논문KCI 등재후보

Diabetes Mellitus and the Risk of Fracture

정민영|정동진|Dong Hyeok Cho|Jin Ook Chung
대한골다공증학회 (THE KOREAN SOCIETY OF OSTEOPOROSIS)|2010.12|OSTEOPOROSIS (The Journal of Korean Society of Osteoporosis)|제8권 제3호|pp. 241-254

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

DiabetesOsteoporosisBone mineral densityFractureBone quality
주제분류기타의약학

초록

The bone mass is known to be decreased in patients with type 1 diabetes, and this is primarily due to osteoblastic dysfunction. A number of epidemiologic studies have consistently shown a significantly higher risk of fractures in type 1 diabetic patients as compared to that of healthy subjects. The data on bone mineral density (BMD) in patients with type 2 diabetes has been inconsistent. However, many recent epidemiologic studies have shown that the osteoporotic fracture risk, and especially at the hip, is also increased in patients with type 2 diabetes, and even in patients with normal or higher BMD. Meanwhile, several studies have shown higher bone mass and a lower fracture risk in subjects with recent onset type 2 diabetes or impaired glucose tolerance with hyperinsulinemia. Poor bone quality and an increased risk of falling are thought to be important contributing factors for the higher fracture risk in patients with type 2 diabetes. Collagen overglycosylation by accumulation of advanced glycation end products (AGE) is thought to be one of the possible mechanisms underlying poor bone quality. The risk of falling in patients with diabetes is increased due to hypoglycemia, visual impairment from retinopathy and cataracts, altered balance, gait problems due to neuropathy and foot ulcers, associated cardiovascular diseases and medication use. Insulin-sensitizing agents, such as thiazolidinediones, are also associated with a higher fracture risk through an increase in bone marrow adiposity and a decrease in osteoblastogenesis. Because diabetes and osteoporosis are highly prevalent chronic diseases in the aging population and the incidences are increasing worldwide, understanding the risk factors that predispose patients to such conditions is very important. On considering the potential mechanisms associated with bone metabolism, adequate glycemic control while minimizing the episodes of hypoglycemia is the most important first step in the medical management to prevent osteoporotic fractures in patients with diabetes.

Abstract

The bone mass is known to be decreased in patients with type 1 diabetes, and this is primarily due to osteoblastic dysfunction. A number of epidemiologic studies have consistently shown a significantly higher risk of fractures in type 1 diabetic patients as compared to that of healthy subjects. The data on bone mineral density (BMD) in patients with type 2 diabetes has been inconsistent. However, many recent epidemiologic studies have shown that the osteoporotic fracture risk, and especially at the hip, is also increased in patients with type 2 diabetes, and even in patients with normal or higher BMD. Meanwhile, several studies have shown higher bone mass and a lower fracture risk in subjects with recent onset type 2 diabetes or impaired glucose tolerance with hyperinsulinemia. Poor bone quality and an increased risk of falling are thought to be important contributing factors for the higher fracture risk in patients with type 2 diabetes. Collagen overglycosylation by accumulation of advanced glycation end products (AGE) is thought to be one of the possible mechanisms underlying poor bone quality. The risk of falling in patients with diabetes is increased due to hypoglycemia, visual impairment from retinopathy and cataracts, altered balance, gait problems due to neuropathy and foot ulcers, associated cardiovascular diseases and medication use. Insulin-sensitizing agents, such as thiazolidinediones, are also associated with a higher fracture risk through an increase in bone marrow adiposity and a decrease in osteoblastogenesis. Because diabetes and osteoporosis are highly prevalent chronic diseases in the aging population and the incidences are increasing worldwide, understanding the risk factors that predispose patients to such conditions is very important. On considering the potential mechanisms associated with bone metabolism, adequate glycemic control while minimizing the episodes of hypoglycemia is the most important first step in the medical management to prevent osteoporotic fractures in patients with diabetes.

참고문헌 (99)

  1. Goodman WG, "Diminished bone formation in experimental diabetes. Relationship to osteoid maturation and mineralization", Diabetes, 33, pp.825~831 (1984)
  2. Vestergaard P, "Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis", Osteoporos Int, 18, pp.427~444 (2007)
  3. Janghorbani M, "Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture", Am J Epidemiol, 166, pp.495~505 (2007)
  4. Singh SR, "Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis", CMAJ, 180, pp.385~397 (2009)
  5. Brown S, "Osteoporosis: An Underappreciated Complication of Diabetes", Cinical Diabetes, 22, pp.10~20 (2004)
  6. Chau DL, "Osteoporosis and diabetes", Curr Diab Rep, 3, pp.37~42 (2003)
  7. Inzerillo AM, "Osteoporosis and diabetes mellitus", Rev Endocr Metab Disord, 5, pp.261~268 (2004)
  8. Suzuki A, "Hypovitaminosis D in type 2 diabetes mellitus: Association with microvascular complications and type of treatment", Endocr J, 53, pp.503~510 (2006)
  9. Kemmis K, "Diabetes and osteoporotic fractures: the role of the diabetes educator", Diabetes Educ, 31, pp.187~196 (2005)
  10. Kemink SA, "Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology", J Endocrinol Invest, 23, pp.295~303 (2000)
  11. Muñnoz-Torres M, "Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus", Calcif Tissue Int, 58, pp.316~319 (1996)
  12. Tuominen JT, "Bone mineral density in patients with type 1 and type 2 diabetes", Diabetes Care, 22, pp.1196~1200 (1999)
  13. Ahmed LA, "Diabetes mellitus and the risk of non-vertebral fractures: the Tromsøo study", Osteoporos Int, 17, pp.495~500 (2006)
  14. Miao J, "Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden", Diabetes Care, 28, pp.2850~2855 (2005)
  15. Nicodemus KK, "Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women", Diabetes Care, 24, pp.1192~1197 (2001)
  16. Schwartz AV, "Diabetes Mellitus: Does it Affect Bone?", Calcif Tissue Int, 73, pp.515~519 (2003)
  17. Weinstock RS, "Bone mineral density in women with type II diabetes mellitus", J Bone Miner Res, 4, pp.97~101 (1989)
  18. Isaia G, "Osteoporosis in type II diabetes", Acta Diabetol Lat, 24, pp.305~310 (1987)
  19. Barrett-Connor E, "Sex differences in osteoporosis in older adults with non-insulindependent diabetes mellitus", Jama, 268, pp.3333~3337 (1992)
  20. Wakasugi M, "Bone mineral density measured by dual energy x-ray absorptiometry in patients with non- insulin-dependent diabetes mellitus", Bone, 14, pp.29~33 (1993)
  21. Vestergaard P, "Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk", Diabetologia, 48, pp.1292~1299 (2005)
  22. Janghorbani M, "Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study", Diabetes Care, 29, pp.1573~1578 (2006)
  23. Bonds DE, "Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study", J Clin Endocrinol Metab, 91, pp.3404~3410 (2006)
  24. de Liefde II, "Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study", Osteoporos Int, 16, pp.1713~1720 (2005)
  25. Schwartz AV, "Older women with diabetes have an increased risk of fracture: a prospective study", J Clin Endocrinol Metab, 86, pp.32~38 (2001)
  26. Strotmeyer ES, "Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study", Arch Intern Med, 165, pp.1612~1617 (2005)
  27. Forséen L, "Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey", Diabetologia, 42, pp.920~925 (1999)
  28. Heath H 3rd, "Diabetes mellitus and risk of skeletal fracture", N Engl J Med, 303, pp.567~570 (1980)
  29. Gerdhem P, "Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus", Osteoporos Int, 16, pp.1506~1512 (2005)
  30. Ottenbacher KJ, "Diabetes mellitus as a risk factor for hip fracture in mexican american older adults", J Gerontol A Biol Sci Med Sci, 57, pp.648~653 (2002)
  31. Holmberg AH, "Risk factors for fragility fracture in middle age. A prospective populationbased study of 33,000 men and women", Osteoporos Int, 17, pp.1065~1077 (2006)
  32. Ivers RQ, "Diabetes and risk of fracture: The Blue Mountains Eye Study", Diabetes Care, 24, pp.1198~1203 (2001)
  33. Meyer HE, "Risk factors for hip fracture in middle-aged Norwegian women and men", Am J Epidemiol, 137, pp.1203~1211 (1993)
  34. Holmberg AH, "The Association between Hyperglycemia and Fracture Risk in Middle Age. A Prospective, Population-Based Study of 22,444 Men and 10,902 Women", J Clin Endocrinol Metab, 93, pp.815~822 (2008)
  35. van Daele PL, "Grobbee DE, Hofman A, et al. Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study", Ann Intern Med, 122, pp.409~414 (1995)
  36. Leslie WD, "Biphasic fracture risk in diabetes: a population-based study", Bone, 40, pp.1595~1601 (2007)
  37. Pedrazzoni M, "Osteocalcin levels in diabetic subjects", Calcif Tissue Int, 45, pp.331~336 (1989)
  38. Carnevale V, "Skeletal involvement in patients with diabetes mellitus", Diabetes Metab Res Rev, 20, pp.196~204 (2004)
  39. Akin O, "Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements", Gynecol Endocrinol, 17, pp.19~29 (2003)
  40. Oz SG, "Evaluation of bone metabolism and bone mass in patients with type-2 diabetes mellitus", J Natl Med Assoc, 98, pp.1598~1604 (2006)
  41. Suzuki K, "Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor", osteoprotegerin (OCIF, Diabetes Res Clin Pract, pp.2005, 68[DOI]
  42. Takizawa M, "Increased bone resorption may play a crucial role in the occurrence of osteopenia in patients with type 2 diabetes: Possible involvement of accelerated polyol pathway in its pathogenesis", Diabetes Res Clin Pract, 82, pp.119~126 (2008)
  43. Lee NK, "Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton", Cell, 130, pp.456~469 (2007)
  44. Kanazawa I, "Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus", J Clin Endocrinol Metab, 94, pp.45~49 (2009)
  45. Im JA, "Relationship between osteocalcin and glucose metabolism in postmenopausal women", Clin Chim Acta, 396, pp.66~69 (2008)
  46. Hwang YC, "The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects", Diabetes Metab Res Rev, 25, pp.768~772 (2009)
  47. Oz SG, "Evaluation of bone metabolism and bone mass in patients with type-2 diabetes mellitus", J Natl Med Assoc, 98, pp.1598~1604 (2006)
  48. Krakauer JC, "Bone loss and bone turnover in diabetes", Diabetes, 44, pp.775~782 (1995)
  49. Botolin S, "Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways", J Cell Biochem, 99, pp.411~424 (2006)
  50. Capoglu I, "Bone turnover markers in patients with type 2 diabetes and their correlation with glycosylated haemoglobin levels", J Int Med Res, 36, pp.1392~1398 (2008)
  51. Bouillon R, "Diabetic bone disease", Calcif Tissue Int, 49, pp.155~160 (1991)
  52. Zhang L, "Bone biomechanical and histomorphometrical investment in type 2 diabetic Goto-Kakizaki rats", Acta Diabetol, 46, pp.119~126 (2009)
  53. Canalis E, "Insulin like growth factors and the local regulation of bone formation", Bone, 14, pp.273~276 (1993)
  54. Raisz LG, "Local and systemic factors in the pathogenesis of osteoporosis", N Engl J Med, 318, pp.818~828 (1988)
  55. Barrett-Connor E, "Does hyperinsulinemia preserve bone?", Diabetes Care, 19, pp.1388~1392 (1996)
  56. Dennison EM, "Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance?", Diabetologia, 47, pp.1963~1968 (2004)
  57. Thrailkill KM, "Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues", Am J Physiol Endocrinol Metab, 289, pp.735~745 (2005)
  58. Campos Pastor MM, "Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study", Osteoporos Int, 11, pp.455~459 (2000)
  59. Gregorio F, "Osteopenia associated with noninsulin- dependent diabetes mellitus: what are the causes?", Diabetes Res Clin Pract, 23, pp.43~54 (1994)
  60. Valerio G, "The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus", Horm Res, 58, pp.266~272 (2002)
  61. Hadjidakis DI, "Papaefstathiou AG, et al. Diabetes in postmenopause: different influence on bone mass according to age and disease duration", Exp Clin Endocrinol Diabetes, 117, pp.199~204 (2009)
  62. Hofbauer LC, "Osteoporosis in patients with diabetes mellitus", J Bone Miner Res, 22, pp.1317~1328 (2007)
  63. Patel S, "Risk Factors for Fractures and Falls in Older Women with Type 2 Diabetes Mellitus", Calcif Tissue Int, 82, pp.87~91 (2008)
  64. Vestergaard P, "Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes", Calcif Tissue Int, 84, pp.45~55 (2009)
  65. Yamamoto M, "Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications", J Bone Miner Res, 24, pp.702~709 (2009)
  66. Ensrud KE, "Body size and hip fracture risk in older women: a prospective study. Study of Osteoporotic Fractures Research Group", Am J Med, 103, pp.274~280 (1997)
  67. Kanazawa I, "Combination of obesity with hyperglycemia is a risk factor for the presence of vertebral fractures in type 2 diabetic men", Calcif Tissue Int, 83, pp.324~331 (2008)
  68. Hwang DK, "The relationship between low bone mass and metabolic syndrome in Korean women", Osteoporos Int, 21, pp.425~431 (2010)
  69. Diamant M, "The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes", J Clin Endocrinol Metab, 90, pp.1495~1501 (2005)
  70. Koh JM, "Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis", Osteoporos Int, 16, pp.1263~1271 (2005)
  71. Dominguez LJ, "Collagen overglycosylation: a biochemical feature that may contribute to bone quality", Biochem Biophys Res Commun, 330, pp.1~4 (2005)
  72. Kume S, "Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone", J Bone Miner Res, 20, pp.1647~1658 (2005)
  73. Saito M, "Role of collagen enzymatic and glycation induced crosslinks as a determinant of bone quality in spontaneously diabetic WBN", Kob rats, 2006, pp.17, 1514~1523
  74. Ding KH, "Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss", Biochem Biophys Res Commun, 340, pp.1091~1097 (2006)
  75. Vashishth D, "Influence of nonenzymatic glycation on biomechanical properties of cortical bone", Bone, 28, pp.195~201 (2001)
  76. Bai XC, "Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB", Biochem Biophys Res Commun, 314, pp.197~207 (2004)
  77. Chen RM, "2,6-Diisopropylphenol protects osteoblasts from oxidative stress-induced apoptosis through suppression of caspase-3 activation", Ann N Y Acad Sci, 1042, pp.448~459 (2005)
  78. Hamada Y, "Histomorphometric analysis of diabetic osteopenia in streptozotocin- induced diabetic mice: a possible role of oxidative stress", Bone, 40, pp.1408~1414 (2007)
  79. Kennedy RL, "Accidents in patients with insulin-treated diabetes: increased risk of lowimpact falls but not motor vehicle crashes--a prospective register-based study", J Trauma, 52, pp.660~666 (2002)
  80. Patel S, "Risk factors for fractures and falls in older women with type 2 diabetes mellitus", Calcif Tissue Int, 82, pp.87~91 (2008)
  81. Adami S, "Bone health in diabetes: considerations for clinical management", Curr Med Res Opin, 25, pp.1057~1072 (2009)
  82. Ali AA, "Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation", Endocrinology, 146, pp.1226~1235 (2005)
  83. Pei L, "Fat's loss is bone's gain", J Clin Invest, 113, pp.805~806 (2004)
  84. Wan Y, "PPAR-gamma regulates osteoclastogenesis in mice", Nat Med, 13, pp.1496~1503 (2007)
  85. Grey A, "Skeletal consequences of thiazolidinedione therapy", Osteoporos Int, 19, pp.129~137 (2008)
  86. Rzonca SO, "Bone is a target for the antidiabetic compound rosiglitazone", Endocrinology, 145, pp.401~406 (2004)
  87. Grey A, "The peroxisome proliferatoractivated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial", J Clin Endocrinol Metab, 92, pp.1305~1310 (2007)
  88. Kahn SE, "Rosiglitazoneassociated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT)", Diabetes Care, 31, pp.845~851 (2008)
  89. Mancini T, "Vertebral fractures in males with type 2 diabetes treated with rosiglitazone", Bone, 45, pp.784~788 (2009)
  90. Dormuth CR, "Thiazolidinediones and fractures in men and women", Arch Intern Med, 169, pp.1395~1402 (2009)
  91. Molinuevo MS, "Effect of Metformin on Bone Marrow Progenitor Cell Differentiation: In Vivo and In Vitro Studies", J Bone Miner Res, 25, pp.211~221 (2010)
  92. Zhen D, "Metformin reverses the deleterious effects of high glucose on osteoblast function", J Diabetes Complications, 24, pp.334~344 (2010)
  93. Cortizo AM, "Osteogenic actions of the antidiabetic drug metformin on osteoblasts in culture", Eur J Pharmacol, 536, pp.38~46 (2006)
  94. Schurman L, "Metformin reverts deleterious effects of advanced glycation endproducts (AGEs) on osteoblastic cells", Exp Clin Endocrinol Diabetes, 116, pp.333~340 (2008)
  95. Nuche-Berenguer B, "Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states", Calcif Tissue Int, 84, pp.453~461 (2009)
  96. Azuma K, "Therapeutic considerations on secondary osteoporosis caused by diabetes mellitus", Clin Calcium, 19, pp.1345~1352 (2009)
  97. Suzuki K, "Effects of combined treatment of insulin and human parathyroid hormone(1-34) on cancellous bone mass and structure in streptozotocininduced diabetic rats", Bone, 33, pp.108~114 (2003)
  98. Epstein S, "Diabetes and fragility fractures - a burgeoning epidemic?", Bone, 43, pp.3~6 (2008)
  99. Keegan TH, "Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial", Diabetes Care, 27, pp.1547~1553 (2004)

이 간행물의 다른 논문 (7건)

Protecting a Woman’s Skeleton김흥열, 정민형pp. 237-240Morphological and Mechanical Changes in Ovariectomized Rat Tibia with Treatments of Ibandronate and Parathyroid Hormone이태용, Padmalosini Muthukumaran, Xiao Yang, Yong Hoow Chanpp. 255-265A Difference of Bone Fracture Rate and Frequency to Have Determined in Diagnosis Standards정수호, 김태희, 이해혁pp. 266-270생체 내 골 발생과정에서 고아핵수용체 Small Heterodimer Partner의 역할: 미세단층촬영기를 이용한 SHP 유전자 결손 생쥐의 골 분석손혜주, 백윤웅, 배인호, 이준행, 김종상, 고정태, 정병철pp. 271-279전완부의 골밀도 측정을 위한 적절한 자세양승오, 정선관, 한만석, 권순태pp. 280-289
원문 보기